US EditionPublished • loading... • Updated
FDA takes aim at Hims and other telehealth services in drug advertising blitz
The FDA targets telehealth firms for promoting unapproved compounded weight loss drugs with misleading claims, issuing over 100 cease and desist letters to protect consumer safety.
- On September 9, the FDA sent a warning letter to Hims & Hers and other companies for making misleading claims suggesting that their compounded semaglutide products are equivalent to FDA-approved medications.
- The FDA action follows its recent determination that GLP-1 drugs no longer meet shortage criteria, ending typical allowances for compounding, though customized prescriptions remain permitted.
- Hims and similar telehealth companies argue their personalized dosages provide extra benefits, but the FDA disputes their compliance with advertising rules and demands removal of misleading statements.
- The FDA issued more than 100 cease-and-desist letters to pharmaceutical companies as part of a Trump administration directive aimed at preventing false or misleading marketing of drugs across television, social media platforms, and internet sites.
- This enforcement could reduce misleading promotion of weight-loss drugs, signaling increased scrutiny of telehealth platforms and potentially altering marketing practices in the industry.
Insights by Ground AI
37 Articles
37 Articles
Associated Press News+34 Reposted by 34 other sources
FDA takes aim at Hims and other telehealth services in drug advertising blitz
The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy.
·United States
Read Full Article
Stocks making the biggest moves midday: WBTN, STLD, HIMS - Finnoexpert
Check out the companies making the biggest moves midday: Webtoon Entertainment — Shares rallied 31% after the company reached a deal to create a digital comic platform for Disney. Webtoon also agreed to sell a 2% equity stake to the media giant. Emerson Electric — The engineering company fell 4.5%. Its management told a JPMorgan conference that fourth-quarter orders are likely to come in at the end of its guidance range, citing weakness in Europ…
Coverage Details
Total News Sources37
Leaning Left6Leaning Right2Center25Last UpdatedBias Distribution76% Center
Bias Distribution
- 76% of the sources are Center
76% Center
L 18%
C 76%
Factuality
To view factuality data please Upgrade to Premium
